A recent filing with the Hong Kong Stock Exchange revealed a notable position change for LEADS BIOLABS-B (09887) on September 3rd. The company's total deposited market value reached HK$669 million, representing a 5.05% stake.
In this transaction, a shareholder transferred 9.71 million shares to Morgan Stanley's Hong Kong securities account, increasing their holding ratio by 4.92%. This shift signals a strategic repositioning of the company's share ownership.
Earlier, LEADS BIOLABS-B had published its interim results for the 2026 fiscal year, reporting revenue of RMB 35.969 million. The company's R&D expenses climbed by 44.92% year-over-year to approximately RMB 191 million, while administrative costs rose 15.5% to RMB 41.4 million. The company posted a net loss of around RMB 222 million for the period, representing a 33.38% increase compared to the prior year.
Comments